The Experts below are selected from a list of 2265 Experts worldwide ranked by ideXlab platform
Alexandra F. Santos - One of the best experts on this subject based on the ideXlab platform.
-
Basophil Activation Test: Mechanisms and considerations for use in clinical trials and clinical practice.
Allergy, 2021Co-Authors: Alexandra F. Santos, Oral Alpan, Hans Jurgen HoffmannAbstract:The Basophil Activation Test (BAT) is a functional assay that measures the degree of degranulation following stimulation with allergen or controls by flow cytometry. It correlates directly with histamine release. From the dose-response curve resulting from BAT in allergic patients, Basophil reactivity (%CD63+ Basophils) and Basophil sensitivity (EC50 or similar) are the main outcomes of the Test. BAT takes into account all characteristics of IgE and allergen and thus can be more specific than sensitization Tests in the diagnosis of allergic disease. BAT reduces the need for in vivo procedures, such as intradermal Tests and allergen challenges, which can cause allergic reactions of unpredictable severity. As it closely reflects the patients' phenotype in most cases, it may be used to support the diagnosis of food, venom and drug allergies and chronic urticaria, to monitor the natural resolution of food allergies and to predict and monitor clinical the response to immunomodulatory treatments, such as allergen-specific immunotherapy and biologicals. Clinical application of BAT requires analytical validation, clinical validation, standardization of procedures and quality assurance to ensure reproducibility and reliability of results. Currently, efforts are ongoing to establish a platform that could be used by laboratories in Europe and in the USA for quality assurance and certification.
-
Basophil Activation Test Reduces Oral Food Challenges to Nuts and Sesame
The journal of allergy and clinical immunology. In practice, 2020Co-Authors: Alexandra F. Santos, Gideon Lack, Matthew Kwok, Marcel Bergmann, Helen A. Brough, Natália Couto-francisco, Valentina Panetta, Diab Haddad, Philippe Eigenmann, Jean-christoph Roger J-p CaubetAbstract:Background Nut allergic patients are often IgE sensitized to other nuts/seeds and need multiple oral food challenges (OFCs) before the safe nuts can be introduced in the diet. However, OFCs are time-consuming and risky procedures. Objective To assess the utility of the Basophil Activation Test (BAT) to predict the allergic status and reduce the need for an OFC in children with 1 or more nut or seed allergies. Methods Participants in the Pronuts study recruited at the Geneva and the London centers were Tested on the BAT to hazelnut, cashew nut, sesame, almond, and peanut, Ara h 1, Ara h 2, Ara h 6, using FlowCAST, a commercially available BAT kit, and flow cytometry. Results The BAT to hazelnut, cashew nut, sesame, almond, and peanut discriminated between allergic and nonallergic children, to the respective nut or seed. The optimal allergen concentration and their optimal, positive, and negative cutoffs were identified for the BAT and the other Tests, for each nut and seed. Using the BAT as a second step in the diagnostic process, after equivocal skin prick Test and IgE to extracts and components, reduced the number of total OFCs by 5% to 15% and positive OFCs by 33% to 75% (except for hazelnut) with 0% false-negatives and a diagnostic accuracy of 96% to 100%. Conclusion The BAT proved to be a useful diagnostic tool, used in a stepwise approach, to predict the allergic status and reduce the number of OFCs in the Pronuts study participants with at least 1 nut allergy willing to consume selected nuts.
-
Basophil Activation Test mechanisms and considerations for use in clinical trials and clinical practice
Authorea Preprints, 2020Co-Authors: Alexandra F. Santos, Oral Alpan, Hans Jurgen HoffmannAbstract:The Basophil Activation Test (BAT) is a functional assay that measures the degree of degranulation following stimulation with allergen or controls by flow cytometry and is directly correlated with histamine release. From the bell-shaped curve resulting from BAT in allergic patients, Basophil reactivity (given by %CD63+ Basophils) and Basophil sensitivity (given by EC50 or similar) are the main outcomes of the Test. BAT takes into account all characteristics of IgE and allergen and thus can be more specific than sensitization Tests in the diagnosis of allergic disease. BAT reduces the need for in vivo procedures, such as intradermal Tests and allergen challenges, which can cause allergic reactions of unpredictable severity. As it closely reflects the patients’ phenotype, it can potentially be used to monitor the natural resolution of food allergies and to predict and monitor clinical response to immunomodulatory treatments, such as allergen-specific immunotherapy and biologicals. Clinical application of BAT requires analytical validation, clinical validation, standardization of procedures and quality assurance to ensure reproducibility and reliability of results. Currently, efforts are ongoing to establish a platform that could be used by laboratories in Europe and in the USA for certification.
-
Basophil Activation Test: Old and New Applications in Allergy.
Current allergy and asthma reports, 2018Co-Authors: Oliver Hemmings, Matthew Kwok, Richard Thomas Mckendry, Alexandra F. SantosAbstract:Purpose of Review The Basophil Activation Test (BAT) using flow cytometry has supplanted traditional methods of measuring Basophil degranulation using histamine and other mediator release, and can be used for clinical applications as well as to explore the immune mechanisms of effector cell response to allergen. This review discusses the advancements made in clinical, diagnostic and laboratory research of allergy utilizing an ever-evolving BAT.
-
Road map for the clinical application of the Basophil Activation Test in food allergy
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2017Co-Authors: Alexandra F. Santos, Wayne G. ShrefflerAbstract:The diagnosis of IgE-mediated food allergy based solely on the clinical history and the documentation of specific IgE to whole allergen extract or single allergens is often ambiguous, requiring oral food challenges (OFCs), with the attendant risk and inconvenience to the patient, to confirm the diagnosis of food allergy. This is a considerable proportion of patients assessed in allergy clinics. The Basophil Activation Test (BAT) has emerged as having superior specificity and comparable sensitivity to diagnose food allergy, when compared with skin prick Test and specific IgE. BAT, therefore, may reduce the number of OFC required for accurate diagnosis, particularly positive OFC. BAT can also be used to monitor resolution of food allergy and the clinical response to immunomodulatory treatments. Given the practicalities involved in the performance of BAT, we propose that it can be applied for selected cases where the history, skin prick Test and/or specific IgE are not definitive for the diagnosis of food allergy. In the cases that the BAT is positive, food allergy is sufficiently confirmed without OFC; in the cases that BAT is negative or the patient has non-responder Basophils, OFC may still be indicated. However, broad clinical application of BAT demands further standardization of the laboratory procedure and of the flow cytometry data analyses, as well as clinical validation of BAT as a diagnostic Test for multiple target allergens and confirmation of its feasibility and cost-effectiveness in multiple settings.
Gianna Moscato - One of the best experts on this subject based on the ideXlab platform.
-
evaluation of Basophil Activation Test in suspected food hypersensitivity
Cytometry Part B-clinical Cytometry, 2017Co-Authors: Patrizia Pignatti, Mona Rita Yacoub, Claudia Testoni, Gianni Pala, Maura Corsetti, Antonio Meriggi, G L Colombo, Gianna MoscatoAbstract:Background Food hypersensitivity is characterized by a wide range of symptoms. The relationship between symptoms and food is more frequently suspected than objectively proven. Basophil Activation Test (BAT) is based on the evaluation of Activation markers on blood Basophils in vitro stimulated with drugs or allergens. The aim of the study was to evaluate the usefulness of BAT when introduced in the routine work-up of suspected food hypersensitivity. Methods BAT was requested in subjects with food adverse reactions when a discrepancy existed among history and skin prick Test (SPT) and/or specific IgE. Data from 150 subjects were analysed using CD63 as Basophil Activation marker. Thirty controls were evaluated for cut-offs. Immunoblots was performed with the sera of representative subjects positive for BAT and negative for SPT and sIgE. Results 1,024 BAT were carried out, the agreement (positive/positive and negative/negative) was 78.5% for BAT vs. SPT and 78.3% for BAT vs. IgE. Atopic patients, but not atopic controls, more frequently had a positive BAT than non-atopic patients (P < 0.0001). Among subjects with positive BAT, those with negative sIgE had lower total IgE, P = 0.001. Nearly 23.3% of all subjects had positive BAT (for at least one Tested food) and both negative sIgE and SPT. Immunoblots revealed the presence of sIgE for the Tested foods in representative patients with positive BAT, negative SPT and sIgE. Conclusion Introduction of BAT in routine of food hypersensitivity, limited to subjects with a discrepancy between history and traditional Tests, might be useful particularly when total IgE are low. © 2015 International Clinical Cytometry Society
-
Evaluation of Basophil Activation Test in suspected food hypersensitivity.
Cytometry. Part B Clinical cytometry, 2015Co-Authors: Patrizia Pignatti, Mona Rita Yacoub, Claudia Testoni, Gianni Pala, Maura Corsetti, Giselda Colombo, Antonio Meriggi, Gianna MoscatoAbstract:Background Food hypersensitivity is characterized by a wide range of symptoms. The relationship between symptoms and food is more frequently suspected than objectively proven. Basophil Activation Test (BAT) is based on the evaluation of Activation markers on blood Basophils in vitro stimulated with drugs or allergens. The aim of the study was to evaluate the usefulness of BAT when introduced in the routine work-up of suspected food hypersensitivity. Methods BAT was requested in subjects with food adverse reactions when a discrepancy existed among history and skin prick Test (SPT) and/or specific IgE. Data from 150 subjects were analysed using CD63 as Basophil Activation marker. Thirty controls were evaluated for cut-offs. Immunoblots was performed with the sera of representative subjects positive for BAT and negative for SPT and sIgE. Results 1,024 BAT were carried out, the agreement (positive/positive and negative/negative) was 78.5% for BAT vs. SPT and 78.3% for BAT vs. IgE. Atopic patients, but not atopic controls, more frequently had a positive BAT than non-atopic patients (P
Patrizia Pignatti - One of the best experts on this subject based on the ideXlab platform.
-
Basophil Activation Test Application in Drug Hypersensitivity Diagnosis: An Empirical Approach.
International archives of allergy and immunology, 2018Co-Authors: Marraccini P, Patrizia Pignatti, Andrea D Apos Alcamo, Rossana Salimbeni, Dario ConsonniAbstract:Background The diagnosis of drug hypersensitivity reactions (DHRs) is based both on clinical history and in vivo Tests, such as specific IgE and cutaneous Tests, when available. Objectives The aim of this work was to evaluate the Basophil Activation Test (BAT) as a supplementary tool for drug challenges and drug allergy diagnosis. Method We evaluated 204 outpatients reporting DHRs. Available serum-specific IgE drugs were determined and cutaneous Tests were performed when appropriate. BAT was performed immediately after blood sampling. The expression of CD63 was evaluated with flow cytometry. The Test was considered positive when CD63 expression was > 5% and the stimulation index (the ratio of the percentage of CD63-expressing cells with drug exposure/percentage of CD63-expressing cells with wash buffer) was > 2. Patients who reported mild to severe reactions and those with a discrepancy between clinical history and BAT underwent a challenge Test. Results The drugs that caused adverse reactions were mainly antibiotics (49%). Non-steroid anti-inflammatory drugs (NSAID) were cited as responsible for DHRs in 37%, with the remaining 14% being due to other drugs. BAT revealed a high specificity (92%) and low sensitivity for antibiotics (40%). For the suspected reactions to penicillin, both the in vitro Tests supported 94% of the diagnoses. We also observed a high specificity in the case of challenge with NSAIDs (100% specificity). Conclusions BAT is effective in discriminating adverse drug reactions, whilst only more critical cases require integrated evaluations and more complex clinical examinations. It is relevant that the concordance of anamnesis and in vitro Tests reduce the need for challenge Testing, limiting them to selected cases.
-
evaluation of Basophil Activation Test in suspected food hypersensitivity
Cytometry Part B-clinical Cytometry, 2017Co-Authors: Patrizia Pignatti, Mona Rita Yacoub, Claudia Testoni, Gianni Pala, Maura Corsetti, Antonio Meriggi, G L Colombo, Gianna MoscatoAbstract:Background Food hypersensitivity is characterized by a wide range of symptoms. The relationship between symptoms and food is more frequently suspected than objectively proven. Basophil Activation Test (BAT) is based on the evaluation of Activation markers on blood Basophils in vitro stimulated with drugs or allergens. The aim of the study was to evaluate the usefulness of BAT when introduced in the routine work-up of suspected food hypersensitivity. Methods BAT was requested in subjects with food adverse reactions when a discrepancy existed among history and skin prick Test (SPT) and/or specific IgE. Data from 150 subjects were analysed using CD63 as Basophil Activation marker. Thirty controls were evaluated for cut-offs. Immunoblots was performed with the sera of representative subjects positive for BAT and negative for SPT and sIgE. Results 1,024 BAT were carried out, the agreement (positive/positive and negative/negative) was 78.5% for BAT vs. SPT and 78.3% for BAT vs. IgE. Atopic patients, but not atopic controls, more frequently had a positive BAT than non-atopic patients (P < 0.0001). Among subjects with positive BAT, those with negative sIgE had lower total IgE, P = 0.001. Nearly 23.3% of all subjects had positive BAT (for at least one Tested food) and both negative sIgE and SPT. Immunoblots revealed the presence of sIgE for the Tested foods in representative patients with positive BAT, negative SPT and sIgE. Conclusion Introduction of BAT in routine of food hypersensitivity, limited to subjects with a discrepancy between history and traditional Tests, might be useful particularly when total IgE are low. © 2015 International Clinical Cytometry Society
-
Evaluation of Basophil Activation Test in suspected food hypersensitivity.
Cytometry. Part B Clinical cytometry, 2015Co-Authors: Patrizia Pignatti, Mona Rita Yacoub, Claudia Testoni, Gianni Pala, Maura Corsetti, Giselda Colombo, Antonio Meriggi, Gianna MoscatoAbstract:Background Food hypersensitivity is characterized by a wide range of symptoms. The relationship between symptoms and food is more frequently suspected than objectively proven. Basophil Activation Test (BAT) is based on the evaluation of Activation markers on blood Basophils in vitro stimulated with drugs or allergens. The aim of the study was to evaluate the usefulness of BAT when introduced in the routine work-up of suspected food hypersensitivity. Methods BAT was requested in subjects with food adverse reactions when a discrepancy existed among history and skin prick Test (SPT) and/or specific IgE. Data from 150 subjects were analysed using CD63 as Basophil Activation marker. Thirty controls were evaluated for cut-offs. Immunoblots was performed with the sera of representative subjects positive for BAT and negative for SPT and sIgE. Results 1,024 BAT were carried out, the agreement (positive/positive and negative/negative) was 78.5% for BAT vs. SPT and 78.3% for BAT vs. IgE. Atopic patients, but not atopic controls, more frequently had a positive BAT than non-atopic patients (P
-
a clinical case of occupational allergy to piperacilline a novel diagnostic method Basophil Activation Test bat
Medicina Del Lavoro, 2013Co-Authors: P Marraccini, Patrizia Pignatti, G Digiesi, L Bordini, M PrevidiAbstract:Background Piperacillin, unlike other antibiotics, rarely causes immediate allergic reactions. Only two cases related to occupational exposure are reported in the literature. Objectives Adoption of new methods for diagnosis of occupational allergy to drugs. Methods An atopic nurse, aged 30 years, was referred to our hospital for an allergic work-related reaction to piperacillin. The patient had suffered two successive episodes with immediate cutaneous reaction, angioedema and dyspnoea after preparing piperacillin. Almost four years previously she had suffered from similar symptoms after taking amoxicillin. She was submitted to a clinical examination and a routine allergic Test, performing also specific IgE (Phadia Pharmacia ImmunoCap) and BAT (Basophil Activation Test) for Beta-lactam antibiotics. Results A positive response to piperacillin was observed in our case using BAT a new non-invasive and safe method, that proved useful for diagnosis of allergy. Moreover, we observed a change from an allergic reaction for therapeutic use of amoxicillin to a work-related adverse reaction to another beta-lactam, piperacillin. Conclusions In previous clinical cases cutaneous and specific challenge Tests were performed for diagnosis. At present, availability of an in vitro Test, such as BAT may provide new diagnostic opportunities, and a useful tool for studying clinical cases other than, in perspective, monitoring exposed workers. Preventive measures were taken in the workplace to lower the risk of sensitization and allergic response. The nurse was transferred to a well controlled job.
Fumiya Hirayama - One of the best experts on this subject based on the ideXlab platform.
-
Sensitivity and specificity of passive immune-Basophil Activation Test to detect allergic transfusion reactions.
Transfusion, 2019Co-Authors: Kazuta Yasui, Nobuki Matsuyama, Yoshihiro Takihara, Hidefumi Kato, Kazuhiko Oka, Kazunori Imada, Atsuko Ueyama, Takafumi Kimura, Fumiya HirayamaAbstract:BACKGROUND The Basophil Activation Test (BAT), performed with patient blood samples and supernatants from transfused blood, was developed to elucidate the mechanistic relationship between transfusion and the resultant allergic transfusion reactions (ATRs). This Test cannot be performed on myelosuppressed patients and neonates because of the absence of Basophils. Therefore, we devised the passive immune Basophil Activation Test (pi-BAT) using patients' plasma and residual transfused blood as sources of immunoglobulin E and allergen, respectively, and the Basophils of healthy volunteers served as a source of the responder cells. The sensitivity and specificity of the pi-BAT, however, remained largely unknown. STUDY DESIGN AND METHODS In this study, the pi-BAT was performed on 31 patients with nonhemolytic transfusion reactions including nine non-ATR and 22 ATR (12 mild and 10 moderate-to-severe) cases to examine its sensitivity and specificity. RESULTS Nine of the 10 cases with moderate-to-severe ATR Tested positive, whereas all the non-ATR cases negative, strongly indicating immunoglobulin E and allergens are involved in the pathogenesis underlying the blood transfusion-triggered adverse effects. CONCLUSION Thus, we propose that pi-BAT can be used to detect moderate-to-severe ATRs and their underlying mechanisms.
-
Clinical utility of a passive immune Basophil Activation Test for the analysis of allergic transfusion reactions.
Transfusion, 2017Co-Authors: Kazuta Yasui, Nobuki Matsuyama, Ikue Okamura-shiki, Takashi Ikeda, Kazuyoshi Ishii, Rika A. Furuta, Fumiya HirayamaAbstract:BACKGROUND In previous studies, we demonstrated that the Basophil Activation Test, which is performed using patient blood and the supernatants from transfused blood components, was able to elucidate not only the causative relationship between allergic transfusion reactions and the transfusion but also the mechanisms behind allergic transfusion reactions. However, for a large number of allergic transfusion reactions, patients are in a state of myelosuppression, and the Basophil Activation Test cannot be performed for these patients because there are insufficient numbers of peripheral blood Basophils. STUDY DESIGN AND METHODS To overcome this obstacle, we developed a passive immune Basophil Activation Test, in which patient plasma and residually transfused blood are used as the patient's sources of immunoglobulin E and allergen, respectively, whereas healthy volunteer Basophils serve as the responder cell source. The passive immune Basophil Activation Test was performed for two patients who had severe allergic transfusion reactions, using supernatants of the residual platelet concentrates and the patients' own immunoglobulin E. RESULTS There were no differences in either surface immunoglobulin E or Activation in response to allergens between untreated Basophils and so-called quasi-Basophils, in which immunoglobulin E was replaced by a third party's immunoglobulin E. In these patients, the supernatants of the residual platelet concentrates exclusively activated Basophils in response to quasi-Basophils onto which the patients' immunoglobulin E, but not a third party's immunoglobulin E, was bound. CONCLUSION The passive immune Basophil Activation Test may help clarify the causal relationship between allergic transfusion reactions and transfused blood, even when patients experience myelosuppression.
-
clinical utility of the Basophil Activation Test for analysis of allergic transfusion reactions a pilot study
Vox Sanguinis, 2017Co-Authors: I Okamura, Kazuta Yasui, Nobuki Matsuyama, Fumiya Hirayama, Takashi IkedaAbstract:Background and Objectives In previous studies, we demonstrated that the Basophil-activating effects of supernatants found in residual-transfused platelet concentrates (PC-SNs) on whole blood Basophils in cases of allergic transfusion reactions (ATRs) could be assessed by the Basophil Activation Test (BAT) in terms of allergen/IgE dependency. However, in these studies, the Basophils were derived from third-party healthy volunteers. In this study, we performed BAT using patients' own blood Basophils to analyse ATRs. Materials and Methods The BAT was performed in two cases of severe ATRs using residual PC-SNs and the patients' own Basophils in the presence and absence of dasatinib, an inhibitor of IgE-mediated Basophil Activation. Results In both cases, PC-SNs exhibited Basophil-activating activity against the patients' Basophils, but not against Basophils from third-party healthy volunteers. In addition, Basophil Activation was inhibited in the presence of dasatinib, indicating that the Basophils were activated in an allergen/IgE-dependent manner. Of note, the Basophils in Case 2, but not in Case 1, were activated by PC-SNs from some unrelated non-haemolytic transfusion reaction cases. Conclusion This pilot study indicates that the BAT may be useful in clarifying the causal relationship between ATRs and transfused blood as well as in elucidating the mechanisms behind ATRs considering the allergen/IgE-dependent pathway.
Mariana Castells - One of the best experts on this subject based on the ideXlab platform.
-
The Contribution of the Basophil Activation Test to the Diagnosis of Hypersensitivity Reactions to Oxaliplatin.
International archives of allergy and immunology, 2018Co-Authors: Cristina Ornelas, Joana Caiado, Alcinda Campos Melo, Manuel Pereira Barbosa, Mariana CastellsAbstract:Cytostatics, mainly oxaliplatin, are widely used to treat oncological diseases. There has been an increase in hypersensitivity reactions to these drugs, mostly IgE-mediated. Skin Tests are the main diagnostic method used but they may induce irritant local reactions and contamination by health care professionals. The main goals of this work were to evaluate the contribution of the Basophil Activation Test (BAT) as a diagnostic tool for hypersensitivity reactions to oxaliplatin, and to compare the expression of CD63 and CD203c molecules. BAT was performed with oxaliplatin in 6 oncological patients with previous documented hypersensitivity reactions to oxaliplatin and in 5 controls (4 oncological patients tolerant to oxaliplatin and 1 healthy control), assessing CD63 and CD203c expression on Basophil population. We found higher values for the Basophil Activation percentage and mean stimulation index for CD203c expression with all oxaliplatin concentrations Tested (most significant at 150 μg/mL: p = 0,0087; p = 0.0222) in the patients than in controls. The same did not occur, with statistical significance, for CD63 expression. When we compared the 2 Activation markers in the patients, we observed a more enhanced expression of CD203c in both evaluations, with statistical significance at the 150-μg/mL concentration (p = 0,026; p = 0,0129). These data show a higher positivity of BAT with oxaliplatin in patients with previous hypersensitivity reactions, when compared to controls, suggesting that BAT may be a promising diagnostic method as an alternative to skin Tests. CD203c appears to play a more prominent role than CD63, which is consistent with what is published in the literature.
-
Basophil Activation Test as a biomarker in allergic patients to platins undergoing rapid desensitization
World Allergy Organization Journal, 2015Co-Authors: Pedro Giavina-bianchi, Matthieu Picard, Joana Caiado, Mariana CastellsAbstract:Background Rapid Drug Desensitization (RDD) has become a cornerstone of the management of immediate hypersensitivity reactions (HSRs) to chemotherapeutic agents, including biologicals. It is the only effective procedure for overcoming HSRs to first-line therapy, thus representing an important advance in patients’ treatment and prognosis. Biomarkers to assess drug sensitization and monitor RDD safety and efficacy are lacking. Preliminary data suggested that in addition to skin Testing, Basophil Activation Test (BAT) could be used to assess patient’s IgE sensitization to platins and provide markers of Activation to evaluate the response to RDD.
-
Basophil Activation Test in allergic patients to platins undergoing rapid desensitization
Clinical and Translational Allergy, 2014Co-Authors: Pedro Giavinabianchi, Matthieu Picard, Joana Caiado, Violeta Regnier Galvao, Mariana CastellsAbstract:Background Desensitization (DST) has become a cornerstone in the management of immediate hypersensitivity reactions (HSRs) to chemotherapic agents. It is the only effective procedure for overcoming HSRs to first-line therapy, thus representing an important advance in patients’ treatment and prognosis. Nevertheless, there are still no good biomarkers to monitor DST safety and effectiveness. The Basophil Activation Test (BAT) has greater applicability in difficult cases with inconclusive diagnosis and when other diagnostic Tests (skin Tests and serum specific IgE) have not been standardized, as in drug-induced reactions. The main goal of our study was to assess BAT as a Test to monitor rapid DST in patients allergic to platins. Method We studied 7 oncologic patients who presented platin allergy and 4 healthy volunteers who had never been exposed to platins. We performed the BAT immediately before DST to platins, assessing CD 203c and CD63 expression on Basophils. All patients were evaluated at least in 2 different DST. Results BAT was positive in 6 patients (85.7%), with increased expression of CD203c and CD63 in 6 and 3 patients, respectively. Subsequent BAT analysis in different DST procedures showed that the Test remained positive with an even greater expression of CD203c and CD63 on Basophils after platins exposure. Some patients with positive BAT reacted during DST, in spite of being premedicated, showing the correlation between BAT results and clinical outcomes. Further investigation is necessary to determine BAT predictive values and its clinical applicability. Conclusion We developed a BAT to platins that presented good sensitivity in our study. Short-term DST to platinum drugs does not induce persistent hyporresponsiveness on Basophils, highlighting the need to maintain DST in allergic patients to platins.